Kathy Giusti and the Multiple Myeloma Research Foundation Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

MMRF annual budget: $12M (2004) [Exhibit 1]
Fundraising efficiency: MMRF spends 85 cents of every dollar on research/programs; 15 cents on overhead [Exhibit 1]
Funding source: 75% of revenue from individual donors; 25% from corporate/events [Paragraph 14]
Clinical trial cost: $50M to $100M for a single drug development cycle [Paragraph 22]

Operational Facts

Staffing: 15 full-time employees [Paragraph 12]
Business model: Venture philanthropy; high-risk, high-reward research funding [Paragraph 18]
Research network: 15 clinical sites across the US [Paragraph 20]
Governance: Founded by Kathy Giusti post-diagnosis; patient-centric board structure [Paragraph 5]

Stakeholder Positions

Kathy Giusti (Founder): Focused on speed to market for new drugs; impatience with traditional slow-moving academic research cycles [Paragraph 8]
Pharmaceutical Partners: Interested in MMRF data but cautious about intellectual property and proprietary data sharing [Paragraph 25]
Patients: Demand for immediate access to experimental therapies and clinical trial transparency [Paragraph 9]

Information Gaps

Specific breakdown of R&D success rates compared to industry averages.
Long-term donor retention rates beyond 3-year cycles.
Quantified impact of MMRF-funded research on FDA drug approval timelines.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

How should MMRF scale its impact while maintaining its agile, high-risk venture philanthropy model in an industry defined by slow, proprietary research?

Structural Analysis

Value Chain: The bottleneck is not capital; it is the translation of basic science into clinical trials. MMRF currently acts as a broker between patients and researchers.
Porter’s Five Forces (Research Landscape): Barriers to entry for new research are defined by regulatory hurdles and capital. MMRF occupies a unique position as a patient-led catalyst that bypasses traditional academic inertia.

Strategic Options

Option 1: The Data Aggregator. Build a proprietary patient data repository to attract pharma partnerships. Trade-offs: High IT cost; requires strict IP management.
Option 2: The Clinical Accelerator. Focus exclusively on funding late-stage clinical trials to shorten approval times. Trade-offs: High capital consumption; binary outcome (success/failure).
Option 3: The Collaborative Hub. Formalize a consortium of pharma, academia, and patients to share data pre-competitively. Trade-offs: Complex governance; requires losing some control.

Preliminary Recommendation

Pursue Option 3. MMRF lacks the capital to compete with Big Pharma in late-stage trials, but it holds the trust of the patient community. Creating a pre-competitive data-sharing consortium is the highest-impact use of its limited resources.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

Month 1-3: Secure commitment from three anchor pharma partners for a data-sharing pilot.
Month 4-6: Establish a legal framework for shared IP that protects patient privacy while allowing research access.
Month 7-12: Onboard clinical sites to the standardized data reporting protocol.

Key Constraints

Pharma Skepticism: Firms are hesitant to share data that could inform competitors.
Academic Silos: Researchers prioritize publications over data utility.

Risk-Adjusted Implementation

The primary risk is a lack of participation. Strategy requires a phased rollout: start with a small, manageable pilot involving non-competitive data points before moving to full clinical results. If participation lags, pivot to a fee-for-service model where pharma pays for access to the patient database.

4. Executive Review and BLUF (Executive Critic)

BLUF

MMRF must transition from a grant-making body to a data-brokering platform. The current model of funding isolated research projects is insufficient to meet the urgency of the patient base. By controlling the data, MMRF gains the influence required to force collaboration between risk-averse pharmaceutical firms. The foundation should stop acting as a charity and start acting as a high-stakes research clearinghouse. This path carries execution risk, but the status quo ensures failure to reach the five-year goal of drug approval acceleration.

Dangerous Assumption

The assumption that pharmaceutical companies will voluntarily share data in a pre-competitive space. Without a mechanism to force this (e.g., controlling access to a proprietary patient registry), they will default to traditional proprietary silos.

Unaddressed Risks

Privacy Liability: Managing a patient-level database creates significant regulatory and legal exposure.
Donor Fatigue: Moving from a feel-good charity model to a cold, data-centric model may alienate the individual donor base that provides 75% of revenue.

Unconsidered Alternative

Direct investment in a virtual biotech entity that holds the IP for promising compounds, essentially becoming the developer rather than the funder. This captures more upside but requires a complete shift in organizational capability.